CN101687788A - 取代的吲哚 - Google Patents

取代的吲哚 Download PDF

Info

Publication number
CN101687788A
CN101687788A CN200780042774A CN200780042774A CN101687788A CN 101687788 A CN101687788 A CN 101687788A CN 200780042774 A CN200780042774 A CN 200780042774A CN 200780042774 A CN200780042774 A CN 200780042774A CN 101687788 A CN101687788 A CN 101687788A
Authority
CN
China
Prior art keywords
compound
deuterium
group
mixture
enantiomorph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200780042774A
Other languages
English (en)
Chinese (zh)
Inventor
T·G·甘特
S·萨沙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auspex Pharmaceuticals Inc
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of CN101687788A publication Critical patent/CN101687788A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Liquid Crystal Substances (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CN200780042774A 2006-10-19 2007-10-19 取代的吲哚 Pending CN101687788A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85324306P 2006-10-19 2006-10-19
US60/853,243 2006-10-19
PCT/US2007/081977 WO2008049116A2 (en) 2006-10-19 2007-10-19 Substituted indoles

Publications (1)

Publication Number Publication Date
CN101687788A true CN101687788A (zh) 2010-03-31

Family

ID=39192780

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780042774A Pending CN101687788A (zh) 2006-10-19 2007-10-19 取代的吲哚

Country Status (10)

Country Link
US (1) US20080103189A1 (enExample)
EP (1) EP2081893B1 (enExample)
JP (1) JP2010507585A (enExample)
CN (1) CN101687788A (enExample)
AT (1) ATE502921T1 (enExample)
AU (1) AU2007310949A1 (enExample)
BR (1) BRPI0715579A2 (enExample)
CA (1) CA2666149A1 (enExample)
DE (1) DE602007013440D1 (enExample)
WO (1) WO2008049116A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104829531A (zh) * 2009-10-26 2015-08-12 大塚制药株式会社 苯并氮杂*化合物
CN106397359A (zh) * 2016-08-31 2017-02-15 重庆华森制药股份有限公司 阿莫曲坦中间体4‑（1‑吡咯烷基磺酰甲基)‑苯肼的制备方法
CN108440452A (zh) * 2017-04-05 2018-08-24 嘉兴市第二医院 一种阿莫曲坦的关键中间体1-（4-氨基-苯甲基磺酰基）吡咯烷的制备方法
CN110831551A (zh) * 2017-05-12 2020-02-21 L/N健康与美容有限责任公司 用于指/趾甲矫正的套件
CN115784965A (zh) * 2021-11-22 2023-03-14 宁波大学 一种7-氟-5-取代色胺类化合物及其制备方法和用途

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2694608A1 (en) * 2007-08-02 2009-02-05 Generics [Uk] Limited A process for the preparation of almotriptan and a synthetic intermediate usable in said process
TWI523652B (zh) 2008-07-15 2016-03-01 泰瑞克公司 氘化苄基苯衍生物及使用方法
UA104005C2 (ru) * 2008-09-03 2013-12-25 Тева Фармасьютикл Индастриз, Лтд. 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
US20110053968A1 (en) 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
US8952337B2 (en) 2009-06-12 2015-02-10 Saint-Gobain Ceramics & Plastics, Inc. High aspect ratio scintillator detector for neutron detection
EP2483406A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
WO2011059080A1 (ja) * 2009-11-16 2011-05-19 第一三共株式会社 同位体置換されたジアミン誘導体
US9073851B2 (en) 2011-10-28 2015-07-07 Board Of Regents, The University Of Texas System Compositions and methods for treating cancer
EA201691582A1 (ru) 2014-02-07 2017-01-30 Оспекс Фармасьютикалз, Инк. Новые фармацевтические препараты
CN107427004B (zh) 2015-01-22 2021-06-08 巴斯夫农业公司 包含苯嘧磺草胺的三元除草组合
WO2017009140A1 (en) 2015-07-10 2017-01-19 BASF Agro B.V. Herbicidal composition comprising cinmethylin and acetochlor or pretilachlor
US11219215B2 (en) 2015-07-10 2022-01-11 BASF Agro B.V. Herbicidal composition comprising cinmethylin and specific inhibitors of protoporphyrinogen oxidase
WO2017009056A1 (en) 2015-07-10 2017-01-19 BASF Agro B.V. Herbicidal composition comprising cinmethylin and dimethenamid
BR112018000482B1 (pt) 2015-07-10 2022-11-22 BASF Agro B.V. Composição herbicida, uso da composição e método para o controle da vegetação indesejada
PL3319434T3 (pl) 2015-07-10 2019-11-29 Basf Agro Bv Kompozycja chwastobójcza zawierająca cynmetylinę i petoksamid
US11219212B2 (en) 2015-07-10 2022-01-11 BASF Agro B.V. Herbicidal composition comprising cinmethylin and imazamox
EA201890260A1 (ru) 2015-07-10 2018-07-31 Басф Агро Б.В. Гербицидная композиция, содержащая цинметилин и пироксасульфон
EP3319442B1 (en) 2015-07-10 2021-09-29 BASF Agro B.V. Method for controlling herbicide resistant or tolerant weeds
AU2016292569B2 (en) 2015-07-10 2021-01-21 BASF Agro B.V. Herbicidal composition comprising cinmethylin and specific pigment synthesis inhibitors
EA201890270A1 (ru) 2015-07-10 2018-08-31 Басф Агро Б.В. Гербицидная композиция, которая содержит цинметилин и специфические хинолинкарбоновые кислоты
WO2018129220A1 (en) * 2017-01-04 2018-07-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
KR20240094040A (ko) * 2017-05-10 2024-06-24 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학적 조성물
JP7237375B2 (ja) * 2018-07-03 2023-03-13 アクスサム セラピューティクス インコーポレイテッド メロキシカムを含有する医薬組成物
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
EP3873883B1 (en) 2019-11-07 2022-12-21 Small Pharma Ltd Method of synthesis
IL312785A (en) 2020-05-19 2024-07-01 Cybin Irl Ltd Denatured Tryptamine Derivatives and Methods of Use
GB2605144A (en) * 2021-03-22 2022-09-28 Small Pharma Ltd Deuterated compounds
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
PL3902541T3 (pl) * 2020-06-02 2022-11-14 Small Pharma Ltd Kompozycje terapeutyczne zawierające deuterowane lub częściowo deuterowane związki n,n-dimetyltryptaminy
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
IT202000014362A1 (it) 2020-06-16 2021-12-16 Indena Spa Processo semisintetico per la preparazione di colchicina
JP2023538402A (ja) * 2020-08-21 2023-09-07 コンパス パスファインダー リミテッド プロドラッグ特性を有する新規サイロシン誘導体
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations
MX2024005955A (es) * 2021-11-18 2024-06-11 Cybin Uk Ltd Formulaciones inyectables e inhalables.
WO2025117661A1 (en) * 2023-11-28 2025-06-05 Quantx Biosciences Us, Inc. Bicyclic heteroaryl compounds

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US579819A (en) 1897-03-30 Automatic feeding device for cigarette-machines
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
IT1170387B (it) * 1982-06-07 1987-06-03 Glaxo Group Ltd Composti eterociclici, procedimento per prepararli e composizioni farmaceutiche che li contengono
GB8419575D0 (en) * 1984-08-01 1984-09-05 Glaxo Group Ltd Chemical compounds
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
IE61488B1 (en) * 1987-08-13 1994-11-02 Glaxo Group Ltd Indole derivatives
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
DK0486666T3 (da) * 1990-06-07 1998-03-30 Zeneca Ltd Terapeutisk heterocykliske forbindelser
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
GB9026998D0 (en) * 1990-12-12 1991-01-30 Glaxo Group Ltd Medicaments
GB9104890D0 (en) 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
GB9125699D0 (en) * 1991-12-03 1992-01-29 Glaxo Group Ltd Device
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
GB9216009D0 (en) * 1992-07-28 1992-09-09 Almirall Lab New indol derivatives
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5457895A (en) * 1993-10-01 1995-10-17 R. P. Scherer Corporation Method of identifying freeze-dried dosage forms
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
WO1997001331A2 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US6586458B1 (en) * 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
HUP0000116A3 (en) 1996-10-01 2000-08-28 Stanford Res Inst Int Taste-masked microcapsule compositions and methods of manufacture
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
WO1998027980A2 (en) 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6376531B1 (en) * 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
PT1104760E (pt) * 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
EP1134290A3 (en) * 2000-03-14 2004-01-02 Pfizer Products Inc. Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors
MXPA03001771A (es) 2000-08-30 2003-06-04 Pfizer Prod Inc Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento.
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
JP4616009B2 (ja) * 2002-12-26 2011-01-19 ポーゼン インコーポレイテッド ＮＳＡＩＤｓおよびトリプタンを含有する多層剤型
DE102005008312A1 (de) * 2005-02-17 2006-08-24 Birds Pharma Gmbh Berolina Innovative Research & Development Services Verwendung deuterierter N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]acatamide und deren pharmazeutisch verträglicher Salze sowie diese Verbindungen enthaltende Arzneimittel
US20080033011A1 (en) * 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
US20090062367A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched eletriptan
US20090069399A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched frovatriptan
US20090076121A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched sumatriptan

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104829531A (zh) * 2009-10-26 2015-08-12 大塚制药株式会社 苯并氮杂*化合物
CN106397359A (zh) * 2016-08-31 2017-02-15 重庆华森制药股份有限公司 阿莫曲坦中间体4‑（1‑吡咯烷基磺酰甲基)‑苯肼的制备方法
CN106397359B (zh) * 2016-08-31 2017-12-05 重庆华森制药股份有限公司 阿莫曲坦中间体4‑(1‑吡咯烷基磺酰甲基)‑苯肼的制备方法
CN108440452A (zh) * 2017-04-05 2018-08-24 嘉兴市第二医院 一种阿莫曲坦的关键中间体1-（4-氨基-苯甲基磺酰基）吡咯烷的制备方法
CN110831551A (zh) * 2017-05-12 2020-02-21 L/N健康与美容有限责任公司 用于指/趾甲矫正的套件
CN110831551B (zh) * 2017-05-12 2022-02-01 L/N健康与美容有限责任公司 用于指/趾甲矫正的套件
CN115784965A (zh) * 2021-11-22 2023-03-14 宁波大学 一种7-氟-5-取代色胺类化合物及其制备方法和用途
WO2023088095A1 (zh) * 2021-11-22 2023-05-25 宁波大学 一种7-氟-5-取代色胺类化合物及其制备方法和用途

Also Published As

Publication number Publication date
WO2008049116A3 (en) 2008-06-05
EP2081893B1 (en) 2011-03-23
JP2010507585A (ja) 2010-03-11
ATE502921T1 (de) 2011-04-15
DE602007013440D1 (de) 2011-05-05
CA2666149A1 (en) 2008-04-24
US20080103189A1 (en) 2008-05-01
BRPI0715579A2 (pt) 2015-05-26
AU2007310949A1 (en) 2008-04-24
WO2008049116A2 (en) 2008-04-24
EP2081893A2 (en) 2009-07-29

Similar Documents

Publication Publication Date Title
EP2081893B1 (en) Substituted indoles
US20080132555A1 (en) Preparation and utility of substituted phenyltetrazoles
US9382237B2 (en) 3,5-diaminopyrazole kinase inhibitors
US20080242687A1 (en) Substituted pyrimidines
KR20100050466A (ko) 섬유증 저해제로서의 치환된 ｎ-아릴 피리디논
US20080194529A1 (en) HIGHLY SELECTIVE and LONG-ACTING PDE5 MODULATORS
US20090291958A1 (en) Substituted PDE5 inhibitors
US20090176792A1 (en) Substituted dibenzhydrylpiperazines
US7772248B2 (en) Preparation and utility of substituted imidazopyridine compounds with hypnotic effects
US20070276042A1 (en) Preparation and utility of substituted carboxylic acid compounds
TW201625597A (zh) 囊性纖維化跨膜傳導調節蛋白之環丙烷甲醯胺調節劑
AU2008282295A1 (en) Substituted indoles
US20110123555A1 (en) Preparation and utility of ccr5 inhibitors
US20080039473A1 (en) Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects
US20080167312A1 (en) Preparation and utility of substituted allylamines
US20090182057A1 (en) Deuterated aminoglycidal compounds
US20090247628A1 (en) Substituted phenylcyclohexylglycolates
CN105979946A (zh) 取代的n-芳基吡啶酮
US20070287734A1 (en) Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
WO2007146890A2 (en) Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
CN101511180A (zh) 取代的羧酸化合物的制备及应用
US20090005309A1 (en) Substituted piperidines
CN101528669A (zh) 氘化氨基缩水甘油基化合物
HK1134080A (en) Preparation and utility of substituted imidazopyridine compounds with hypnotic effects
HK1134754A (en) Preparation and utility of substituted carboxylic acid compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20100331